Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple ...
The trial assesses Precem-TcT efficacy and safety alone or with bevacizumab in mCRC patients after previous therapies.
Merck (MRK) shares rose nearly 5% in early trade on Friday after the company said a European medicines committee issued a ...
May 21 () - Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another ‌part ...
H.C. Wainwright downgraded Summit Therapeutics (SMMT) to Neutral from Buy, citing overhang from a new late-stage trial readout for sac-TMT, a lung cancer therapy developed by Merck (MRK) in ...
AstraZeneca (AZN), and AbbVie (ABBV) are among the winners of positive drug recommendations in the EU this week. Read more ...
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in ...
Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial ...
Merck KGaA made its largest acquisition in a decade in April 2025 when it snapped up Connecticut rare disease specialist ...
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda ...
Merck received a positive opinion from the European Medicines Agency backing approval of its Keytruda-Padcev combination for a subset of bladder patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results